NeuroSearch's license partner Abbott initiates clinical Phase I study with ABT-560

NeuroSearch's development and license partner Abbott has enrolled and dosed the
first patients in a clinical Phase I study with the drug candidate ABT-560,
which has treatment potential within a variety of CNS disorders. 

ABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown
promise in preclinical models relevant for the treatment of cognitive deficits. 

According to the terms of the license agreement, Abbott has all rights to
ABT-560 and will finance all costs relating to the development and
commercialisation of the drug. NeuroSearch will receive milestone payments as
well as royalties on Abbott's global sales, if the drug is successfully
commercialised. 

The initiation of the Phase I study with ABT-560 releases a milestone payment
to NeuroSearch. 

NeuroSearch maintains financial expectations for 2007 of a loss before
recognition of associates and other equity interests in the region of DKK 80 -
100 million. 


Asger Aamund
Chairman of the Board


Contact persons:	Phone: 
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate
Communications 
	
+45 4460 8212 or +45 4017 5103


NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the
Nordic Exchange Copenhagen A/S. Our core business covers the development of
novel drugs, based on a broad and well-established drug discovery platform
focusing on ion channels and CNS disorders. A substantial part of the company's
activities are partner financed through a broad alliance with GlaxoSmithKline
(GSK) and collaborations with among others Abbott and Astellas. The drug
pipeline comprises 11 clinical development programmes: ACR16 in Huntington's
disease (Phase III preparation), tesofensine in obesity/type 2 diabetes (Phase
II), NS2359 in depression (Phase II) and ADHD (Phase II) in partnership with
GSK, NS1209 in epilepsy and pain (Phase II), ABT-894 in ADHD (Phase II) and
pain (Phase I) in partnership with Abbott, ACR16 in schizophrenia (Phase I) in
partnership with Astellas, ACR325 in bipolar disorder (Phase I) and ABT-107 as
well as ABT-560 for the treatment of various CNS diseases - both (Phase I) in
collaboration with Abbott. In addition, NeuroSearch has a broad portfolio of
preclinical drug candidates and holds equity interests in several biotech
companies.